European Companies Search Engine
UK funding (£1,822,581): Maximising Efficiency of Liquid Phase Oligo Synthesis (MELOS) Ukri1 Jun 2023 UK Research and Innovation, United Kingdom
Overview
Text
Maximising Efficiency of Liquid Phase Oligo Synthesis (MELOS)
| Abstract | Oligonucleotides (oligos) are sequences of nucleotides monomers which usually contain between 15-25 nucleotides/ nucleotide-analogues, they offer promising treatment for a wide range of medical conditions. There are now 15 oligo drugs which have been approved between the EMA and FDA. In recent years, an **increasing number of oligos in clinical trials** have shown excellent results for diseases with large patient populations. For example, Inclisiran, an oligo developed for the treatment of cardiovascular disease (thousands of patients), was approved in Europe in 2020 and is available on the NHS since 2021\. It is estimated Inclisiran will treat 300,000 patients in the UK in the next three years. While Solid Phase Synthesis (SPS) is the dominant manufacturing process to produce oligos it presents several limitations. The main challenges comprise: **the lack of scalability** (~10-20kg batch sizes maximum), the **high costs** (£800-£1000/g of oligos) and the **heavy environmental burden** associated with the process (~4300kg/kg PMI). This creates a critical need for sustainable, ton-per-annum-scale oligo production routes to enable oligos to deliver patient benefits in large populations. The Grand Challenge 'GC3' consortium (comprising Novartis, AstraZeneca, Alnylam, Exactmer, CPI) is developing Nanostar Sieving, a **breakthrough new technology based on Liquid Phase Synthesis** (LPS) to manufacture oligos. For oligo manufacture, this platform is positioned to provide ease of scaling under GMP conditions (100kg/batch), with high crude purity oligos (70-90%) and use of similar phosphoramidite monomer equivalents (1.5 equivalents/cycle). Maximising Efficiency of Liquid-phase Oligo Synthesis (MELOS) is a UK based collaboration between Exactmer, Queen Mary University of London (QMUL), CPI and AstraZeneca, seeking to build on the success of GC3\. This 24-month project will focus on **a step change in the process efficiency and sustainability of the Nanostar Sieving platform** for the synthesis of oligos on large scale. The current chemistry will be further developed by using Nanostar hubs and monomers with better membrane selectivities and higher solubilities. Further step changes include integration of a solvent recycling loop within the Nanostar Sieving process, seeking a **reduction of 40% in the total Process Mass Intensity** (PMI) compared to SPS technology. A solvent drying device will allow in-process water removal that will reduce required phosphoramidites equivalents to close to stoichiometric (i.e., <1.1 equivalents). In-line, real-time analysis will be implemented to monitor the quality of the recycled solvent. Furthermore, this work is required to ensure the **highest quality of product is obtained with minimal environmental impact, and at reduced costs**. In addition to demonstrating the efficiency of the solvent recycling and drying device within the Nanostar Sieving technology, the consortium will also retrofit this device into a Solid Phase Synthesizer. Implementing solvent recovery through membrane separation will provide a competitive edge for CDMOs and other manufacturing sites offering this capability which will widen the impact of the project to existing manufacturing assets |
| Category | Collaborative R&D |
| Reference | 10062179 |
| Status | Active |
| Funded period start | 01/06/2023 |
| Funded period end | 30/11/2025 |
| Funded value | £1,822,581.00 |
| Source | https://gtr.ukri.org/projects?ref=10062179 |
Participating Organisations
| EXACTMER LIMITED |
£702,910.00 |
| CENTRE FOR PROCESS INNOVATION LIMITED |
£447,567.00 |
| QUEEN MARY UNIVERSITY OF LONDON |
£672,104.00 |
| ASTRAZENECA UK LIMITED |
The filing refers to a past date, and does not necessarily reflect the current state. The current state is available on the following page: Exactmer Ltd., Harrogate.
The visualizations for "Exactmer Ltd. - UK funding (£1,822,581): Maximising Efficiency of Liquid Phase Oligo Synthesis (MELOS)"
are provided by
North Data
and may be reused under the terms of the
Creative Commons CC-BY license.
